Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
50 Results for "
KRAS4B
" in MedChemExpress (MCE) Product Catalog:
Products (50)
50 Results for "KRAS4B" in MCE Product Catalog:
1
1 Cited Publications
Target:
Research Areas:
LB42708 is a potent, selective and orally active farnesyltransferase inhibitor. LB42708 inhibits farnesylation of H-Ras, N-Ras and K-Ras4B with IC50s of 0.8 nM, 1.2 nM and 2.0 nM, respectively .
Synonyms: DS11252927
Research Areas:
D927 (DS11252927) is an orally active glucose transporter type 4 (GLUT4) translocation activator with an EC50 of 0.14 μM. D927 enhances the binding affinity of PI3Kα catalytic subunit p110α to canonical RAS proteins (KRAS4A, KRAS4B) and RRAS, RRAS2, MRAS. D927 activates the PI3Kα-AKT pathway (increasing phosphorylation of AKT, p70S6 kinase) without affecting the RAF-ERK1/2 pathway. D927 improves hyperglycemia in type 1 and type 2 diabetes mice model. D927 can be used for the study of glucose homeostasis disorders and diabetes .
Target:
Research Areas:
FTI 276 TFA is a farnesyltransferase (FTase) inhibitor with an IC50 of 0.5 nM, and it exhibits selectivity for FTase over geranylgeranyltransferase I (GGTase I). FTI 276 TFA blocks the farnesylation of H-Ras and K-Ras4B, causes inactive Ras-Raf complexes to accumulate in the cytoplasm, and inhibits constitutive MAPK activation. FTI 276 TFA reduces the number, incidence and volume of tumors, and restricts the growth of tumors expressing activated K-ras. FTI 276 TFA can be used in research related to pulmonary adenoma .
Kras4B G12D-IN-1 is a Kras4B G12D inhibitor with anticancer effects. Kras4B G12D-IN-1 decreases Kras protein expression in mouse embryonic fibroblasts (MEF) expressing Kras4B G12D (WO2016179558A1, Comp 994566) .
Cat. No.: HY-115489
CAS No.: 171744-11-9
GGTI-286, a potent and cell-permeable GGTase I inhibitor, is 25-fold more potent (IC50=2 μM) than the corresponding methyl ester of FTI-276 (HY-15873A). GGTI-286 selectively inhibits geranylgeranylation of Rap1A over farnesylation of H-Ras in NIH3T3 cells (IC50s=2 and >30 μM, respectively). GGTI-286 also potently inhibits oncogenic K-Ras4B stimulation with an IC50 of 1 μM .
Cat. No.: HY-115489A
Target:
Research Areas:
GGTI-286 TFA, a potent and cell-permeable GGTase I inhibitor, is 25-fold more potent (IC50=2 μM) than the corresponding methyl ester of FTI-276 (HY-15873A). GGTI-286 TFA selectively inhibits geranylgeranylation of Rap1A over farnesylation of H-Ras in NIH3T3 cells (IC50s=2 and >30 μM, respectively). GGTI-286 TFA also potently inhibits oncogenic K-Ras4B stimulation with an IC50 of 1 μM .
Cat. No.: HY-117935
CAS No.: 181141-66-2
GGTI-286 hydrochloride, a potent GGTase I inhibitor, is 25-fold more potent (IC50=2 μM) than the corresponding methyl ester of FTI-276 (HY-15873A). GGTI-286 hydrochloride selectively inhibits geranylgeranylation of Rap1A over farnesylation of H-Ras in NIH3T3 cells (IC50s =2 and >30 μM, respectively). GGTI-286 hydrochloride also potently inhibits oncogenic K-Ras4B stimulation with an IC50 of 1 μM .
Cat. No.: HY-183625
PCA-IN-1 is a polyisoprenylated cysteinyl amide (PCA) inhibitor that acts on multiple KRAS mutant subtypes. PCA-IN-1 dissociates KRAS4B from its transport chaperones, prevents its localization to the plasma membrane, and blocks downstream oncogenic signaling pathways. PCA-IN-1 inhibits colony formation of KRAS-mutant lung cancer cells, induces sustained long-term growth inhibition, and suppresses cell migration. PCA-IN-1 is applicable to the research of KRAS-mutant lung cancer .
Cat. No.: HY-P70233A
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: rHuGTPase KRAS4B, His; Ki-Ras; c-K-ras; KRAS2; RASK2; CFC2
Cat. No.: HY-P704746
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: rHuGTPase KRAS4B, His; Ki-Ras; c-K-ras; KRAS2; RASK2; CFC2
Species:
Source:
Cat. No.: HY-P704750
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: rHuGTPase KRAS4B, His; Ki-Ras; c-K-ras; KRAS2; RASK2; CFC2
Cat. No.: HY-P704747
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: rHuGTPase KRAS4B, His; Ki-Ras; c-K-ras; KRAS2; RASK2; CFC2
Cat. No.: HY-P704748
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: rHuGTPase KRAS4B, His; Ki-Ras; c-K-ras; KRAS2; RASK2; CFC2
Cat. No.: HY-P704749
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: rHuGTPase KRAS4B, His; Ki-Ras; c-K-ras; KRAS2; RASK2; CFC2
Cat. No.: HY-P704751
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: rHuGTPase KRAS4B, His; Ki-Ras; c-K-ras; KRAS2; RASK2; CFC2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
